Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1
Journal for ImmunoTherapy of Cancer, 2019 Background Several predictive biomarkers are currently approved or are under investigation for the selection of patients for checkpoint blockade. Tumor PD-L1 expression is used for stratification of non-small cell lung (NSCLC) patients, with tumor ...
Kellie N. Smith +40 more
doaj +1 more source
In vivo application of recombinant interleukin 2 in the immunotherapy of established cytomegalovirus infection [PDF]
, 1987 We have shown in a murine model system for cytomegalovirus (CMV) disease in the immunocompromised host that in vivo application of recombinant human IL-2 (rhIL-2) can enhance the antiviral effect of a limited number of CD8+T lymphocytes, not only in ...
Reddehase, Matthias J. +9 more
core +1 more source
Recent Advances and Challenges in Cancer Immunotherapy [PDF]
, 2022 SIMPLE SUMMARY: Immunotherapy helps a person’s immune system to target tumor cells. Recent advances in cancer immunotherapy, including immune checkpoint inhibition, chimeric antigen receptor T-cell therapy and cancer vaccination, have changed the ...
Yiping Yang +5 more
core +1 more source
The alarmin IL33 orchestrates type 2 immune-mediated control of thymus regeneration
Nature Communications, 2023 As the primary site of T-cell development, the thymus dictates immune competency of the host. The rates of thymus function are not constant, and thymus regeneration is essential to restore new T-cell production following tissue damage from environmental ...
Emilie J. Cosway +7 more
doaj +1 more source
Immunotherapy: Review of the Existing Evidence and Challenges in Breast Cancer [PDF]
, 2023 Breast cancer (BC) is a representative malignant tumor that affects women across the world, and it is the main cause of cancer-related deaths in women. Although a large number of treatment methods have been developed for BC in recent years, the results ...
Xiaoyi Zhang +7 more
core +1 more source
Intralymphatic immunotherapy [PDF]
World Allergy Organization Journal, 2015 Gold Standard allergen-specific immunotherapy is associated with low efficacy because it requires either many subcutaneous injections of allergen or even more numerous sublingual allergen administrations to achieve amelioration of symptoms. Intralymphatic vaccination can maximize immunogenicity and hence efficacy.
Senti G, Kündig TM
openaire +4 more sources
Immune Environment and Immunotherapy in Endometrial Carcinoma and Cervical Tumors [PDF]
, 2023 Endometrial cancer (EC) is the seventh most common tumor in women, and prognosis of recurrent and metastatic disease is poor. Cervical cancer (CC) represents the fifth most common gynecological cancer.
Hasan, Uzma +9 more
core +1 more source
Intratumoral neoadjuvant immunotherapy based on the BO-112 viral RNA mimetic
OncoImmunology, 2023 BO-112 is a poly I:C-based viral mimetic that exerts anti-tumor efficacy when intratumorally delivered in mouse models. Intratumoral BO-112 synergizes in mice with systemic anti-PD-1 mAbs and this combination has attained efficacy in PD1-refractory ...
Maite Alvarez +16 more
doaj +1 more source
Clinical Applications of Immunotherapy for Recurrent Glioblastoma in Adults [PDF]
, 2023 Glioblastoma (GBM) is the most common malignant primary brain tumor in adults. Despite standard therapies, including resection and chemoradiation, recurrence is virtually inevitable. Current treatment for recurrent glioblastoma (rGBM) is rapidly evolving,
Meagan Mandabach Olivet +6 more
core +1 more source
Effect of specific immunotherapy added to pharmachologic treatment and allergen avoidance in allergic asthma [PDF]
, 2004 Although several studies support the efficacy of specific immunotherapy in allergic asthma, its benefit compared with that of standardized pharmacologic intervention remains unknown.
PIACENTINI, Giorgio +5 more
core +1 more source